An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy

Dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new type of oral hypoglycemic drugs which can promote glucose excretion in the kidney. Studies have shown that dapagliflozin has renoprotective effect in the treatment of type 2 diabetes. However, the underlying mechanism re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Zhenyu, Xie, Ting, Liu, Tianhao, Chen, Zedong, Yu, Linde, Zhang, Chao, Luo, Jincheng, Chen, Liguo, Zhao, Xiaoshan, Xiao, Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533015/
https://www.ncbi.nlm.nih.gov/pubmed/36213291
http://dx.doi.org/10.3389/fendo.2022.967822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533015/
https://www.ncbi.nlm.nih.gov/pubmed/36213291
http://dx.doi.org/10.3389/fendo.2022.967822

Ejemplares similares